Translating Scientific Advances In Inner Ear Biology Into Novel Therapies For People With Hearing Disorders


Decibel Therapeutics is a hearing company focused on discovering and developing new therapies to protect, repair and restore hearing. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to define the underlying biological causes of hearing loss and develop a pipeline of breakthrough therapies targeted to specific indications and populations. 


Year Invested: 2015
Location: Cambridge, Mass.
Visit: www.decibeltx.com

Recent News

July 6, 2017
Decibel Therapeutics Announces Investment from GV to Expand Capabilities for Biological Target Identification in Hearing Loss and Tinnitus

May 17, 2017
Decibel Therapeutics Opens New Headquarters and The Fenway’s First Lab

February 13, 2017
Decibel Therapeutics Presents at 2017 Annual Association for Research in Otolaryngology (ARO) Meeting

Read More News

Associated Team Members

Kevin Starr
Partner

Craig Muir
Partner/Chief Technology Officer